PCI-27483
CAS No. 871266-63-6
PCI-27483 ( PCI27483; PCI-27483; PCI 27483 )
Catalog No. M17634 CAS No. 871266-63-6
PCI 27483 is an activated coagulation factor VIIa inhibitor with antithrombotic effects in a baboon model of arterial thrombosis.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 71 | In Stock |
|
10MG | 120 | In Stock |
|
25MG | 203 | In Stock |
|
50MG | 306 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePCI-27483
-
NoteResearch use only, not for human use.
-
Brief DescriptionPCI 27483 is an activated coagulation factor VIIa inhibitor with antithrombotic effects in a baboon model of arterial thrombosis.
-
DescriptionPCI-27483 is a reversible small-molecule inhibitor of activated factor VII (factor VIIa) with potential antineoplastic and antithrombotic activities. FVII, a serine protease, becomes activated (FVIIa) upon binding with TF forming the FVIIa/TF complex, which induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2). Upon subcutaneous administration, factor VIIa inhibitor PCI-27483 selectively inhibits factor FVIIa in the VIIa/TF complex, which may prevent PAR-2 activation and PAR2-mediated signal transduction pathways, thereby inhibiting tumor cell proliferation, angiogenesis, and metastasis of TF-overexpressing tumor cells.
-
SynonymsPCI27483; PCI-27483; PCI 27483
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCoagulation factor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number871266-63-6
-
Formula Weight596.57
-
Molecular FormulaC26H24N6O9S
-
Purity98%
-
Solubility——
-
SMILESc1cc2c(cc1C(=N)N)[nH]c(c1cc(cc(c1O)c1c(ccc(c1)S(=O)(=O)N)O)CC(=O)NC(CC(=O)O)C(=O)O)n2
-
Chemical Name(S)-2-(2-(5-(5-carbamimidoyl-1H-benzo[d]imidazol-2-yl)-2',6-dihydroxy-5'-sulfamoyl-[1,1'-biphenyl]-3-yl)acetamido)succinic acid.
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gómez-Outes, A, et al. New parenteral anticoagulants in development. Ther. Adv. Cardiovasc. Disc. 5(1), 33-59 (2011).
molnova catalog
related products
-
iCDK9
iCDK9 (i-CDK9) is a potent, highly selective CDK9 inhibitor (IC50<0.4 nM, CDK9-CycT1 kinase), exhibits >600-fold selectivity toward CDK1-CycB, CDK2-CycA, CDK4-CycD1, CDK7-CycH-MAT1 and CDK8-CycC.
-
Purvalanol B
A potent, cell-permeable, selective inhibitor of CDK with IC50s of 6, 6, 9, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, and cdk5-p35 respectively.
-
NU-2058
An ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively; inhibits human tumor cells with a mean GI50 of 13±7 uM.